Transgene and BioInvent Receive Approval From ANSM to Proceed With Phase I/IIa Trial of Anti-CTLA4-armed Oncolytic Virus BT-001 in Solid Tumors
The Pharma Data
JANUARY 18, 2021
We would like to thank the investigators and the clinical teams for their support and look forward to treating the first patients with this first Invir.IO generated oncolytic virus candidate to enter clinical development” said Dr. Maud Brandely, MD, PhD, Chief Medical Officer of Transgene. Transgene has an ongoing Invir.IO
40 
Let's personalize your content